Investors
Why Invest in Preservation Bio?
Preservation Bio is revolutionizing transfusion medicine with our innovative ex vivo platelet additive, designed to extend platelet shelf life and reduce waste. With platelets critical for cancer patients, trauma care, and bleeding disorders, our technology addresses a $1.2 billion market and tackles global shortages exacerbated by historic lows in donations. Backed by a $2.05 million SBIR Phase II grant and cutting-edge research from top academic institutions, we are advancing toward clinical trials, offering investors a unique opportunity to support a transformative healthcare solution.
Investment Highlights
Revolutionary RHOA Inhibitor: Our proprietary ex vivo additive targets RHOA to prevent cold storage damage, doubling platelet shelf life and improving functionality.
Strong Academic and Industry Partnerships: Backed by cutting-edge research from Cincinnati Children’s Hospital and the University of Cincinnati, along with a $2.05 million SBIR Phase II grant to advance development.
Addressing a $1.2 Billion Market Opportunity: The platelet transfusion market faces significant unmet needs due to short shelf life and waste; our solution offers a scalable, impactful alternative.
Experienced Leadership Team: Our team combines decades of expertise in transfusion medicine, molecular biology, and biopharmaceutical commercialization, driving innovation and scalability.
Recent News
Read about our latest developments, including funding rounds, partnership announcements, and progress in our pipeline.
